Carpmaels & Ransford has again been ranked as a leading patent firm in the areas of pharma and biotechnology, medical technology, chemistry, digital communication and computer technology, and electronics in this year’s edition of the JUVE Patent UK rankings.
The firm was also recommended in the Solicitor firms in litigation category.
12 partners from the firm were named as recommended individuals by the guide: Camilla Balleny, Jennifer Antcliff, Ian Kirby, David Wilson, Harvey Adams, Stephen Duffield, Hugh Goodfellow, Cameron Marshall, Edward Oates, Gary Small, James Warner, and Daniel Wise.
JUVE includes the following comments about the firm:
For many years now, the patent litigation practice at Carpmaels & Ransford has enjoyed a strong position in the London market, which extends across Europe when it comes to both patent prosecution and litigation in the life sciences sector.
The firm has a particularly strong position in pharma and biotech patents, with one client attesting to its “outstanding and in-depth expertise” regarding pharma patents. The firm also has an outstanding Europe-wide reputation in SPCs, such as in its work for Janssen against Teva over Xeplion.
Carpmaels clearly plays in the top European league with Hoffmann Eitle and Vossius & Partner when it comes to EPO oppositions and appeals. One client praised it as “a very good firm”. The firm’s patent attorneys, including Harvey Adams, Cameron Marshall, Hugh Goodfellow and Edward Oates operate at the forefront of the market.
The firm is also well-seasoned in combining its mixed expertise for clients. For example, in the past year the firm’s litigators and patent attorneys were heavily involved in several infringement and revocation proceedings for various Johnson & Johnson subsidiaries.
On the litigation side, the small but growing team around Ian Kirby and David Wilson focuses primarily on life sciences disputes. Only few other London litigation practices, such as Allen & Overy and Hogan Lovells, have a presence in pharma proceedings on the side of originator companies to rival that of Carpmaels.
Last year, next generation litigator Camilla Balleny’s work for Bristol-Myers Squibb and Jennifer Antcliff’s work on several cases for Johnson & Johnson subsidiary Janssen Pharmaceuticals boosted the team’s market presence. This, together with the addition of Agathe Michel-de Cazotte, helps lend the team the necessary clout for future UPC cases.
Read the full item here